Stay updated with breaking news from Antonio Passaro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.
Adding amivantamab to chemotherapy can improve outcomes in patients with EGFR-mutant advanced NSCLC whose disease progressed on osimertinib.
Amivantamab-based regimens improved oncologic outcomes, but with more side effects